Park Ha Biological Technology Co., Ltd.
Park Ha Biological Technology Co., Ltd. Fundamental Analysis
Park Ha Biological Technology Co., Ltd. (PHH) shows moderate financial fundamentals with a PE ratio of 21.08, profit margin of 20.09%, and ROE of 38.00%. The company generates $0.0B in annual revenue with weak year-over-year growth of -3.14%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 60.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze PHH's fundamental strength across five key dimensions:
Efficiency Score
ExcellentPHH demonstrates superior asset utilization.
Valuation Score
ExcellentPHH trades at attractive valuation levels.
Growth Score
WeakPHH faces weak or negative growth trends.
Financial Health Score
ExcellentPHH maintains a strong and stable balance sheet.
Profitability Score
ExcellentPHH achieves industry-leading margins.
Key Financial Metrics
Is PHH Expensive or Cheap?
P/E Ratio
PHH trades at 21.08 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, PHH's PEG of 0.21 indicates potential undervaluation.
Price to Book
The market values Park Ha Biological Technology Co., Ltd. at 6.70 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 12.78 times EBITDA. This signals the market has high growth expectations.
How Well Does PHH Make Money?
Net Profit Margin
For every $100 in sales, Park Ha Biological Technology Co., Ltd. keeps $20.09 as profit after all expenses.
Operating Margin
Core operations generate 33.32 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $38.00 in profit for every $100 of shareholder equity.
ROA
Park Ha Biological Technology Co., Ltd. generates $15.52 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Park Ha Biological Technology Co., Ltd. generates strong operating cash flow of $948.38K, reflecting robust business health.
Free Cash Flow
Park Ha Biological Technology Co., Ltd. generates strong free cash flow of $863.89K, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.03 in free cash annually.
FCF Yield
PHH converts 8.78% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
21.08
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.21
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.70
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.18
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.87
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.38
vs 25 benchmark
ROA
Return on assets percentage
0.16
vs 25 benchmark
ROCE
Return on capital employed
0.51
vs 25 benchmark
How PHH Stacks Against Its Sector Peers
| Metric | PHH Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 21.08 | 23.01 | Neutral |
| ROE | 38.00% | 1228.00% | Weak |
| Net Margin | 20.09% | -4010.00% (disorted) | Strong |
| Debt/Equity | 0.05 | 0.78 | Strong (Low Leverage) |
| Current Ratio | 1.87 | 2.35 | Neutral |
| ROA | 15.52% | -157546.00% (disorted) | Strong |
PHH outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Park Ha Biological Technology Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
155.83%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthEPS CAGR
198.68%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthFCF CAGR
292.92%
Industry Style: Defensive, Dividend, Low Volatility
High Growth